西格列汀对糖尿病肾病患者转化生长因子-β1、血小板源性生长因子BB的影响∗

摘要

目的：探讨西格列汀对糖尿病肾病患者血糖及转化生长因子-β1(TGF-β1)、血小板源性生长因子 BB (PDGF-BB)的影响。方法82例二甲双胍单药治疗血糖控制不佳的2型糖尿病肾病患者加用西格列汀治疗6个月,观察治疗前后血糖、尿白蛋白排泄率(AER)、血清 TGF-β1和 PDGF-BB 水平,分析西格列汀治疗和 AER、血清TGF-β1、PDGF-BB 的关系。结果加用西格列汀治疗后空腹血浆葡萄糖(fasting plasma glucose,FPG)、餐后血糖(postprandial blood glucose,PPG)、糖化血红蛋白(HbA1c)、胰岛岛素抵抗指数(HOMA-IR)等下降,HOMA-IS 升高(P <0.05)；AER 和血清 TGF-β1、PDGF-BB 水平均下降(P <0.05)。结论西格列汀治疗能够降低糖尿病肾病患者的血糖、血清 TGF-β1、PDGF-BB 和 AER 水平。%Objective To study the effects of sitagliptin on transforming growth factor-β1 (TGF-β1 )and platelet derived growth factor-BB(PDGF-BB)in patients with diabetic nephropathy.Methods 82 diabetic patients with poor glycemic control undergoing single antidiabetic-drug treatment with metformin were added with sitagliptin for 6 months in their treatment.Levels of blood glucose,AER,FBG,TGF-β1and PDGF-BB were measured before and after treatment and the relationship between sitagliptin treatment and AER,plasma TGF-β1,PDGF-BB were analyzed.Results The levels of FPG,PPG,HbA1c and HOMA-IR were decreased while HOMA-IS was increased (P <0.05 )after treatment with sitagliptin.Meanwhile,the levels of AER,plasma TGF-β1 and PDGF-BB were decreased(P < 0.05 ).Conclusion Treatment with sitagliptin can significantly reduce levels of glucose,plasma TGF-β1,PDGF-BB and AER in patients with diabetic nephropathy.